WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Axogen to pay $200M cash for BioCircuit and its sutureless NerveTape FDA codifies eight De Novo device types as Class II, three years after granting them Precera Medical buys Additive Metal Services to bring metal injection molding in house Powerful Medical wins a De Novo for AI that flags heart attacks on a 10-second ECG Zenflow says four US centers have run the first commercial Spring cases FDA says it has never authorized a clear aligner sold without a prescription CraniUS clears a patient-specific cranial plate under K261058 FDA clears Emboline's Emboliner, a TAVR filter tested head to head against Sentinel Petal Surgical shows its histotripsy robot and says first-in-human is close Axogen to pay $200M cash for BioCircuit and its sutureless NerveTape FDA codifies eight De Novo device types as Class II, three years after granting them Precera Medical buys Additive Metal Services to bring metal injection molding in house Powerful Medical wins a De Novo for AI that flags heart attacks on a 10-second ECG Zenflow says four US centers have run the first commercial Spring cases FDA says it has never authorized a clear aligner sold without a prescription CraniUS clears a patient-specific cranial plate under K261058 FDA clears Emboline's Emboliner, a TAVR filter tested head to head against Sentinel Petal Surgical shows its histotripsy robot and says first-in-human is close

Breakthrough

Nutromics wins Breakthrough designation for a microneedle patch that reads vancomycin levels

MedDevice Startups Staff · 2 days ago · 2 min read · Via Company release

FDA granted Nutromics a Breakthrough Device Designation on September 10 for its first product, a wearable patch that continuously measures vancomycin in patients on the antibiotic. The company calls the platform Lab-on-a-Patch. It reads levels through DNA-based sensors on microneedles rather than by drawing blood.

Vancomycin is the first use case because the dosing is hard and the volume is large. About 2.9 million US patients a year get the drug, often for sepsis, and the therapeutic window is tight enough that clinicians chase trough levels with repeat draws. Nutromics published first-in-human data in Nature Biotechnology in February 2026 and is targeting a US launch in 2027.

The company runs out of Brunswick, in Melbourne, and San Diego. Breakthrough designation buys interactive review and senior FDA attention. It does not shorten the review clock and it does not settle the pathway, which for a first-of-kind continuous molecular monitor is the harder question.

Questions & Answers

What did Nutromics receive FDA Breakthrough Device Designation for?

On September 10, 2026, FDA granted Nutromics a Breakthrough Device Designation for a wearable patch that continuously monitors vancomycin levels for therapeutic drug monitoring. The patch uses DNA-based sensors on microneedles and is the company's first product.

Where is Nutromics based and when does it plan a US launch?

Nutromics operates from Brunswick in Melbourne, Australia and from San Diego. The company is targeting a US launch of its vancomycin monitoring patch in 2027.

Has the Nutromics vancomycin patch been cleared by FDA?

No. As of September 2026 the Nutromics patch holds a Breakthrough Device Designation only, which gives the company interactive FDA review but is not a clearance or an approval. The device is still in development.

← Back to Startups